A study presented at American Headache Society Annual Scientific Meeting; June 19-22, 2025; Minneapolis has revealed that ...

Treatment needs vary among patients with cluster headache, according to a poster presented at the American Headache Society ...

Erenumab is not associated with significant reductions in weekly attacks in patients with chronic cluster headache vs placebo ...

Television is always in season these days. It can be a distraction from the world’s ills, transporting us back in time or ...

Television is always in season these days. It can be a distraction from the world’s ills, transporting us back in time or immersing us in the first blush of young love; it can also help us work ...

June is Migraine Awareness Month, a time to shed light on one of the most common and often misunderstood neurological ...

Among children and adolescents with episodic migraine, fremanezumab significantly reduced monthly migraine days.

Final results from the Phase IV PEARL trial show that 66% of patients treated with Ajovy for episodic migraine and more than ...

The full results of the phase IV RESOLUTION trial were presented at the European Academy of Neurology 2025 Annual Congress, where Vyepti® (eptinezumab) demonstrated statistically significant ...

Once-daily rimegepant 75 mg is effective and well-tolerated for short-term prevention of fasting-related headache in adults ...

Atogepant 60 mg vs rimegepant and galcanezumab for episodic migraine prevention has superior efficacy, with comparable safety ...

Lundbeck’s Vyepti (eptinezumab) has met both the primary and secondary endpoints in the placebo-controlled Phase IV ...